Switching from Mounjaro to Wegovy

Written byDr Mohamed ObiedallaMBBS, MRCGP, BMSGP / Medical Director GPhC No. 2061908
Reviewed byDr Mohamed ObiedallaMPharm, MBA, PhD, MRCPharmSuperintendent Pharmacist GPhC No. 2061908
Published
Last reviewed Our clinical review process
Switching from Mounjaro to Wegovy

If you've spent months gradually increasing Mounjaro, the thought of switching to Wegovy and starting from the beginning again can feel frustrating.

So do you always have to start Wegovy at 0.25 mg?

The answer requires some nuance.

There is no official Mounjaro-to-Wegovy conversion

Mounjaro contains tirzepatide.

Wegovy contains semaglutide.

Although both affect GLP-1 pathways, they are different medicines with different dose ranges. There is no MHRA-approved table saying that a specific Mounjaro dose equals a particular Wegovy dose.

The licensed Wegovy initiation schedule begins at 0.25 mg once weekly, increasing gradually.

switching from mounjaro to wegovy

Important: This table should not be interpreted as a dose-equivalence or self-switching guide. There is no direct milligram-for-milligram conversion between Mounjaro and Wegovy. The appropriate starting dose and timing of a switch should be determined by the prescribing clinician.

But what if I'm already established on a GLP-1?

Previous treatment exposure is still clinically relevant.

A prescriber considering a switch will want to know:

  • your current Mounjaro dose
  • how long you have taken it
  • when you took your last injection
  • how well you tolerated it
  • whether you experienced nausea or vomiting
  • your current weight and treatment goals.

In some clinical services, previous GLP-1 exposure may form part of an individualised switching decision. However, this should not be described as a true dose equivalence.

Should the medicines overlap?

No.

Mounjaro and Wegovy should not be used together simply to make a transition smoother.

The timing of a switch should be agreed with the prescribing clinician.

What might feel different?

Mounjaro acts at both the GIP and GLP-1 receptors, whereas Wegovy acts at the GLP-1 receptor.

Some patients notice differences in hunger, fullness or gastrointestinal effects when switching.

That does not necessarily mean the new treatment isn't working, particularly while the dose is being established.

How Pharmulous can help

Pharmulous does not treat switching as a self-service dose conversion.

Our clinicians can review your previous treatment, current dose, tolerability and treatment gap and determine an appropriate Wegovy plan.

We recognise that previous GLP-1 experience matters — but safety remains more important than trying to match two medicines milligram for milligram.

References

  1. Wegovy SmPC.
  2. Mounjaro vs semaglutide SURMOUNT-5 trial.
  3. MHRA. GLP-1 medicines: what you need to know.

Sign up to our newsletter

Sign up to be the first to know about promotions and news.